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Key Clinical Message
This case report describes an individual with brain calcifications, cognitive
decline, motor dysfunction, and hypocalcaemia. Exome sequencing revealed a
previously reported variant in the CASR gene and a variant of uncertain signifi-
cance in PDGFRB. The clinical phenotype is likely explained by the CASR variant,
but we discuss how the PDGFRB variant could also participate in the phenotype.
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CASR, Fahr’s syndrome, autosomal dominant, hypocalcaemia, PDGFRB, pri-
mary familial brain calcification, whole-exome sequencing.
Introduction
Calcifications of the basal ganglia were first described in
1850 [1], and since that time intracranial calcifications
have been linked to multiple disorders and even inciden-
tally discovered at a low frequency within healthy popu-
lations [2–5]. Primary familial brain calcification (PFBC,
or Fahr’s syndrome) is a primarily autosomal dominant
disorder characterized by progressive, peri-capillary bilat-
eral calcifications of the brain, especially in the basal
ganglia, but also seen in the cerebellum, thalami, brain-
stem, and subcortical white matter [3, 6, 7]. To identify
PFBC, clinicians rely on several core criteria to diagnose
patients, including progressive neurological and/or psy-
chological symptoms, the elimination of other
underlying etiologies, such as trauma or metabolic disor-
ders, and a family history of basal ganglia calcification
[3, 7, 8].
Despite these guidelines, reported phenotypes vary
considerably [3, 8], and there is possible confusion with
other calcification disorders due to over 35 different
descriptive terms being used within the literature [3].
With the increased utilization of clinical genetic testing,
this diagnostic uncertainty has been reduced, and sev-
eral genes have been linked to PFBC in recent years
[9–12]. Here, we report a novel variant of uncertain
significance (VUS) in the platelet-derived growth factor
receptor beta subunit (PDGFRB) gene as well as a likely
pathogenic variant of the calcium-sensing receptor
(CASR) gene in the same individual.
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Materials and Methods
Ethical compliance
The patient consented to sample collection and subse-
quent analysis under a protocol approved by the institu-
tional review board of the Mayo Clinic. Written informed
consent was obtained from the patient for publication
and accompanying images.
Whole-exome sequencing
Clinical whole-exome sequencing (WES) was performed
by GeneDx (XomeDxPlus). Briefly, genomic DNA was
extracted from the proband. As described in the clinical
testing methodology by GeneDx, the Agilent Clinical
Research Exome capture kit was used for exome enrich-
ment and sequencing was performed on an Illumina
HiSeq 2000 that generates 100 bp paired-end reads. Bidi-
rectional sequences were assembled, aligned to reference
gene sequences based on human genome build GRCh37/
UCSC hg19, and analyzed for sequence variants using a
proprietary analysis tool (Xome Analyzer, GeneDx). San-
ger sequencing was used to confirm all disease relevant
variants identified in this individual. Variant filtration
techniques were performed per standard commercial
methods for GeneDx. Sequence alterations were reported
according to the Human Genome Variation Society
(HGVS) nomenclature guidelines.
Clinical Report
Case description
The patient is a 73-year-old man of northern European
origin, who presented with a several year history of pro-
gressive dysarthria and mild aphasia. The patient reported
that he was “. . .not able to put sentences together.” He
further asserted that he had “lost [his] voice,” following
each of two previous hip replacement surgeries. Similarly,
laryngospasm and tetany were reported. The patient’s neu-
rological examination revealed mild to moderate cognitive
impairment, characterized by deficits in concentration,
executive dysfunction, diminished visual constructional
and visuospatial skills, slowed verbal fluency, diminished
naming, and inefficient memory retention. These findings
were consistent with mild cognitive impairment, secondary
to frontal, temporal, and parietal lobe dysfunction. Speech
and language assessments revealed a mixed dysarthria with
hyperkinetic and hypokinetic features. There was also mild
oral apraxia and mild impairment in motor programming.
His most recent imaging examinations (Fig. 1) revealed
symmetric, bilateral calcifications of the cerebral deep
white matter, basal ganglia, thalami, medial occipital cor-
tices, and deep cerebellar white matter. There was no evi-
dence of atrophy. Prior computed tomography (CT) and
magnetic resonance imaging (MRI) examinations also
detected extensive calcifications, notably of the basal gan-
glia, but also across other regions. On MRI, this mani-
fested as increased signal in T1-weighted images in the
corona radiata, centrum semiovale, thalami, dentate
nuclei, and cerebellar white matter. In these earlier
images, there was evidence of atrophy reported that dis-
proportionately affected the frontal and parietal lobes,
and to a milder extent, the cerebellum. The patient had
previously undergone MRI in 2009 after suffering a
stroke. His records from this time make no mention of
brain calcifications, suggesting that this finding was pro-
gressive and has persisted for at least 2 years.
Given the link between basal ganglia calcification and
metabolic/endocrine dysregulation, the patient was tested
for hypoparathyroidism. He displayed low calcium at
8.6 mg/dL (reference range ≥22 years: 8.9–10.1 mg/dL),
but creatinine, parathyroid hormone (PTH), and thyroid-
stimulating hormone (TSH) were within normal ranges.
Genetic testing
There were no related clinical findings in the proband’s
family (see Fig. 2), although his paternal grandfather and
son are reported to have either attempted (former) or com-
mitted suicide (latter). Notably, depression has been linked
with PFBC. The patient also has a son with a history of
Graves’ disease with hyperthyroidism. Previous testing by
Fulgent for two of the most common PFBC-associated
genes (PDGFB and SLC20A2) did not detect any variants,
therefore the patient underwent WES through the Mayo
Clinic Department of Clinical Genomics. WES revealed
variants in two genes (Table 1) possibly associated with the
patient’s phenotype: a likely pathogenic variant in the
CASR gene (Chr3(GRCh37): g.122003232A>G, NM_
000388.2: c.2431A>G, NP_000379.2: p.(Met811Val)) and a
novel variant of uncertain significance in PDGFRB (Chr5
(GRCh37): g.149512314G>A, NM_002609.3: c.1126C>T,
NP_002600.1: p.(Arg376Trp)). The p.(M811V) variant in
exon 7 of CASR was not observed in approximately 123,136
exomes and 15,496 genomes in the Genome Aggregation
Database (gnomAD). The variant results in a conservative
amino acid substitution, which occurs at a position that is
conserved across species, down to Danio rerio (zebrafish).
In silico analysis predicts this variant is likely damaging to
the protein structure and/or function (see Table 2). The
p.(R376W) variant in PDGFRB was seen in 3/272342 alleles
in gnomAD [13]; http://gnomad.broadinstitute.org/). The
variant results in a nonconservative amino acid substitu-
tion, which is predicted to impact secondary protein
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structure. The variant falls at the end of exon 7, but is not
predicted to impact splicing based on in silico splice predic-
tion tools. This substitution occurs at a position that is
moderately conserved across species (including in Gallus
gallus). In silico analysis [14] predicts this variant is likely
damaging to the protein structure and/or function (see
Table 2).
The proband’s asymptomatic 72-year-old brother was
also tested and found to have the PDGFRB variant but
not the CASR (see pedigree in Fig. 2) variant.
Discussion
Intracranial mineral deposition is common to a number of
disorders, including certain neurodegenerative and meta-
bolic diseases, although it also occurs at low levels in the
general population and may be related to the normal aging
process [2–5]. In PFBC, calcium is deposited in perivascu-
lar areas of the brain, especially the basal ganglia and
cerebellar white matter, and is most commonly linked to
movement and cognitive dysfunctions [3, 6, 8, 15].
In this case study, multiple MRI and head CT scans
uncovered extensive bilateral calcifications in a patient
originally presenting with dysarthria and reductions in
learning and memory abilities. Consistent with PFBC, the
patient’s calcifications were found in the deep white mat-
ter of the cerebrum and cerebellum, thalami, and basal
ganglia. WES uncovered two heterozygous genetic vari-
ants in this patient: one novel VUS in PDGFRB and one
likely pathogenic variant in CASR.
The first gene, PDGFRB (MIM #173410), produces a
homodimeric tyrosine kinase (TK) receptor (PDGF-Rb)
that can bind multiple ligands, including PDGF-B (plate-
let-derived growth factor subunit B), which, along with
the receptor, has been linked to PFBC in a number of
recent studies [6, 9, 11, 16–19]. PDGF-Rb is thought to
be involved in angiogenesis and hematopoiesis during
development, and Keller et al. [9] proposed that the accu-
mulation of calcium in PDGF-Rb/PDGF-B linked PFBC
cases may be related to a dysfunctional blood–brain bar-
rier (BBB).
Most reported cases of PDGFRB variants have been
classified as gain-of-function, leading to disorders such as
infantile myofibromatosis (MIM #228550), Kosaki over-
growth disorder (MIM #616592) [20], and premature
aging disorders (MIM #601812) [21]. However, several
variants in or near the split-TK domain of the receptor
have been found in patients with basal ganglia calcifica-
tions [6, 11, 18, 19]. Physically closest to our novel vari-
ant (c.1126C>T, p.(R376W)) is a missense variant at
codon 371 (p.N371K, c.1113C>G), although the patient
in this case was diagnosed with Cornelia de Lange syn-
drome and had no mention of brain calcifications [22].
Lastly, whilst our variant falls close to a splice site,
Figure 1. CT scan in the axial plane showing extensive bilateral calcification of basal ganglia.
Figure 2. Three-generation family pedigree. Proband indicated with
arrow. Both the proband and his asymptomatic brother share a PDGFRB
variant, whilst the proband additionally carries the CASR variant.
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splicing predictions were not in favor of a strong effect
on splicing.
The second genetic variant uncovered by WES in the
CASR gene (c.2431A>G, p.(M811V)) (MIM #601199) has
been reported previously in a family with hypoparathy-
roidism, hypocalcaemia, and relative hypercalciuria [23].
Similarly, the proband described here has hypocalcaemia
and borderline low-normal parathyroid hormone and
serum magnesium levels, which is characteristic of autoso-
mal dominant hypocalcaemia caused by an activating CASR
variant [24]. The variant was shown to segregate with the
hypocalcaemic phenotype in three generations of affected
individuals in this family, while unaffected family members
were negative for the variant, providing strong evidence for
its pathogenicity. Activating CASR variants lead to defective
sensing and regulation of serum calcium levels, resulting in
a reduction in parathyroid hormone and maintained
hypocalcaemia. Interestingly, 50% of patients presenting
with hypercalciuric hypocalcaemia syndrome type 1 are
estimated to have asymptomatic hypocalcaemia, and over
35% have ectopic and/or basal ganglia calcifications [24].
As PFBC is partially diagnosed based on the exclusion of
underlying metabolic etiology [3, 7, 8], the presence of
hypocalcaemia combined with two potentially contributing
genetic variants makes diagnosis difficult. It is possible that
both variants contribute to this patient’s complex pheno-
type. For example, in one reported case, a patient rapidly
developed extensive unilateral calcifications in both the
white and gray matter several weeks after an ischemic
stroke in the same brain region [25]. The rapid, ectopic
accumulation of calcium was thought to occur due to the
pre-existing imbalanced ratio of phosphate to calcium and
the weakened vasculature at the site of the stroke [25]. This
report by Wityk, combined with findings of disrupted BBBs
in both mice with PDGF-B variants [9] and postmortem
PFBC human tissue [26], strengthens the hypothesis that
an impaired BBB/vascular system could lead to increased
susceptibility to mineral deposition in the brain, especially
when combined with metabolic imbalances. However,
metabolic dysfunction has been reported to cause ectopic
mineral deposition independently of any reported increase
in BBB or vascular vulnerability, as seen by Kurozumi et al.
[27] and Schouten et al. [23]. Additionally, a mouse model
experiment performed by Vanlandewijck et al. [28] found
that PGDFBret/ret mice actually had healthier BBBs in brain
regions prone to calcification as compared to regions not
prone to calcification [28]. The association between BBB
impairment and increased mineralization must then merit
further investigation.
In this report, the clinical presentation of the patient
seems to more closely fit that of PFBC compared to that
of activating CASR variants, although his hypocalcaemia
is certainly attributable to the latter. In PFBC, the mostT
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commonly reported manifestation is movement disorder,
closely followed by cognitive and cerebellar impairments,
and speech disorder [3, 6, 8, 9]. In this case, the patient
originally sought medical attention due to cognitive
decline and speech impairment, although some tremulous
movements in his upper limbs, muscular fasciculations,
and dysphagia were noted during examination. Other less
commonly reported symptoms of PFBC include stroke [6,
15] and vertigo [29], both of which were identified in this
patient prior to or during treatment. In this case, the ver-
tigo was successfully ameliorated using Epley chair reposi-
tioning. Additionally, Mufaddel & Al-Hassani [8]
reported that in 40% of patients, psychiatric features are
often the first presenting symptom of PFBC and the most
common of these is depression. Interestingly, although
the patient asserts that he has no current or previous epi-
sodes of depression, there is a documented family history
of this condition and the patient notes that he has had
increased emotional reactivity in recent years.
Follow-up genetic testing of the patient’s asymptomatic
72-year-old brother revealed the same heterozygous variant
in PDGFRB (c.1126C>T, p.(R376W)), but no changes in
CASR were detected. However, this information is the
extent of available family history, as no other testing,
including CT imaging, was completed for the brother, and
other family members were unavailable for testing. Conse-
quentially, we were unable to use the brother’s information
to determine if the isolated PDGFRB variant is associated
with any specific features of the patient’s phenotype. The
lack of familial confirmation is the largest limitation of the
current report as it is impossible to determine if PFBC or
hypocalcaemia are present in untested members of the
family, the mode of inheritance, and whether either of the
variants segregate with the ectopic calcifications, cognitive
symptoms, and/or hypocalcaemia as reported in the pro-
band. The limited information provided by the brother’s
genetic testing and his apparent lack of symptoms may
provide clues as to the causative variant in the proband;
however, incomplete penetrance and a variable age of onset
have commonly been reported for PFBC [3, 6, 15, 30]. Of
note, PFBC and hypocalcaemia caused by CASR changes
are thought to be inherited mainly via an autosomal domi-
nant pattern [9, 19, 23, 26, 27].
Conclusions
In conclusion, we report a 73-year-old man with bilateral
basal ganglia calcifications and two variants in CASR and
PDGFRB with a possible blended phenotype. We were
unable to gather substantial information on familial phe-
notypes to further investigate the effects of the PDGFRB
VUS. Despite this, the existence of past cases of PDGFRB
variants causing basal ganglia calcifications suggests that
the VUS could be implicated in the mineralization
present in our proband.
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